Inactive Instrument

Other languages Vifor Pharma Xetra

Equities

G2AA

CH0364749348

Other languages

Unlock all the news: Be the first to know and act before the market!

European Commission Solicits Feedback on Vifor Pharma's Anticompetition Commitments	19/04
CSL Vifor Announces Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis	02/23/02
Court Cancels Public Shares of Vifor Pharma after Merger with CSL	14/22/14
Cancellation of remaining publicly held registered shares of Vifor Pharma AG	14/22/14
Ferinject® approved in Chinafor the treatment of iron deficiency in adult patients	28/22/28
Iron Deficiency Day 2022: CSL Vifor calls to take iron seriously	25/22/25
Rhythm Biosciences Expands Executive Management Team, Registers Diagnostic Blood Test With New Zealand	03/22/03
Approval of extension of exemptions from SIX disclosure and publicity obligations	20/22/20
Australia's CSL raises annual profit forecast on Swiss acquisition	17/22/17
Global markets live: Darktrace, Intel, Twitter, Meta, Uber...	12/22/12
Vifor Pharma Gets Approval To Delist From Swiss Bourse	12/22/12
Approval of delisting of Vifor Pharma AG's registered shares	12/22/12
Swissmedic OKs ChemoCentryx's Combo Therapy For Rare Blood Vessel Disease	28/22/28
Fitch Pulls Vifor Pharma's Rating After CSL Takeover	25/22/25
Vifor, Travere's Application for Rare Kidney Disease Drug Under Review in EU	23/22/23
CSL Vifor and Travere Therapeutics announce EMA has accepted for review the Conditional Marketing Authorization application for sparsentan for the treatment of IgA Nephropathy	22/22/22
Vifor-Fresenius Medical Care JV Wins US Infringement Case Against Teva	22/22/22
VFMCRP announces U.S. Court upholds validity of Velphoro® patent	22/22/22
Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 2022	19/22/19
VFMCRP - Tavneos (avacopan) recommended by England's NICE for the treatment of AAV (GPA/MPA)	18/22/18

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Vifor Pharma Xetra

Equities

G2AA

CH0364749348

Other languages

Filters